Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
04/2003
04/17/2003WO2003030922A2 Bestrophin and bestrophin homologous proteins involved in the regulation of energy homeostasis
04/17/2003WO2003030918A1 Pharmaceutical product or food supplement and intermediate product to be used therewith
04/17/2003WO2003030895A1 Styryl acrylonitrile compounds and their use to promote myelopoiesis
04/17/2003WO2003030885A2 Modulation of the adventitial tool-like receptor
04/17/2003WO2003030873A1 Therapeutic biological product and method for formation of new vascularised bone
04/17/2003WO2003030870A1 Prolonged release biodegradable microspheres and method for preparing same
04/17/2003WO2003030866A1 Stable galenic freeze-dried pharmaceutical preparation of recombined carbohydrate-binding polypeptides
04/17/2003WO2003030865A1 Pro-micelle pharmaceutical compositions
04/17/2003WO2003030860A1 Skin care compositions containing peptide copper complexes and retinol, retinol derivatives, or a mixture thereof
04/17/2003WO2003030836A2 Neuronal regeneration
04/17/2003WO2003030834A2 Cyclosporin analogs for the treatment of lung diseases
04/17/2003WO2003030832A2 Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer
04/17/2003WO2003030829A2 Liposome-encapsulated insulin formulations
04/17/2003WO2003030828A2 Nociceptin-based analgesics
04/17/2003WO2003030827A2 Compositions for and methods of treating and preventing sirs/sepsis
04/17/2003WO2003030826A2 Antisense modulation of insulin-like growth factor binding protein 5 expression
04/17/2003WO2003030825A2 CCAAT/ENHANCER BINDING PROTEIN-β (C/EBPβ IS A MOLECULAR TARGET FOR CANCER TREATMENT
04/17/2003WO2003030824A2 Methods and compositions for treating dermal lesions
04/17/2003WO2003030720A2 Materials and methods for preventing or reducing scar formation
04/17/2003WO2003030617A2 Antisense modulation of creb expression
04/17/2003WO2003030616A2 21132, a human g-protein coupled receptor family member and uses therefor
04/17/2003WO2003030613A2 Methods of treating liver fibrosis and hepatitis c virus infection
04/17/2003WO2003022301A3 Use of lh in controlled ovarian hyperstimulation
04/17/2003WO2003013591A3 Pharmaceutical composition containing caspase-8 and/or caspase-9 useful for overcoming glucocorticoid- and cancer therapy-induced apoptosis resistance of tumours
04/17/2003WO2003013585A8 Mifaxin agonists and antagonists for use in the treatment of metabolic
04/17/2003WO2003000707A3 Antisense modulation of superoxide dismutase 1, soluble expression
04/17/2003WO2002096903A3 Chemical derivatives and the use thereof as an anti-telomerase agent
04/17/2003WO2002094985A3 Beta-secretase substrates and uses thereof
04/17/2003WO2002094863A3 INTERFERON-α INDUCED GENE
04/17/2003WO2002085943A3 Nucleic acids of the human abcc12 gene, vectors containing such nucleic acids and uses thereof
04/17/2003WO2002085930A3 Immunomodulating agents from parasitic worms and method for isolation thereof
04/17/2003WO2002085928A3 Modified cyclosporine which can be used as a pro-drug and use thereof
04/17/2003WO2002083727A3 Nucleic acid sequences of hyperplasies and tumors of the thyroid
04/17/2003WO2002081706A3 Regulation of human phosphatase-like protein
04/17/2003WO2002078728A3 Peptides for the treatment of wound contracture
04/17/2003WO2002078620A3 Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
04/17/2003WO2002077188A3 Human serine/threonine kinase
04/17/2003WO2002076486A3 Histidine-rich glycoprotein
04/17/2003WO2002072622A3 Vaccine antigens against infection by chlamydia trachomatis
04/17/2003WO2002070706A3 Interleukin-8 homologous polypeptides and therapeutic uses thereof
04/17/2003WO2002069902A3 Cyclosporins for the treatment of respiratory diseases
04/17/2003WO2002060163A9 Methods for increasing bone formation and enhancing bone accretion
04/17/2003WO2002058718A3 Use of compositions containing pdgf-bb for promoting angiogenesis
04/17/2003WO2002053752A3 Isolated human phosphatase proteins, nucleic acid molecules encoding human phosphatase proteins, and uses thereof
04/17/2003WO2002051237A9 Helicobacter proteins, nucleic acids and uses thereof
04/17/2003WO2002050289A9 Methods for the production of multimeric proteins, and related compositions
04/17/2003WO2002050284A3 Oxidoreductases
04/17/2003WO2002048708A3 Assay for anti-viral agent
04/17/2003WO2002047713A3 Composition containing a mixture of growth factor for the treatment of renal injury
04/17/2003WO2002039923A3 Inhibition of alpha-2 hs glycoprotein (ahsg/fetuin) in obesity and insulin control of glucose homeostasis
04/17/2003WO2002033085A3 Wisp polypeptides and therapeutical applications thereof
04/17/2003WO2002032445A3 Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof
04/17/2003WO2002029036A3 Lipid metabolism enzymes
04/17/2003WO2002028900A3 Tach: new tnf-receptor family nucleic acids and polypeptides
04/17/2003WO2002024891A3 B7-like molecules and uses thereof
04/17/2003WO2002020619A9 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3)
04/17/2003WO2002018579A3 57242, a novel human g protein-coupled receptor family member and uses therefor
04/17/2003WO2002018575A3 Genes expressed in the cell cycle
04/17/2003WO2002012341A3 Her-2/neu fusion proteins
04/17/2003WO2002010402A3 Isolation of drosophila and human polynucleotides encoding par-1 kinase, polypeptides encoded by the polynucleotides and methods utilizing the polynucleotides and polypeptides
04/17/2003WO2002004511A3 CHROMOSOME 3p21.3 GENES ARE TUMOR SUPPRESSORS
04/17/2003WO2001076573A3 Combination of at least two compounds selected from an at1-receptor antagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups
04/17/2003WO2001072773A3 Genes isolated from dendritic cells, gene products and methods employing the same
04/17/2003WO2001057275A3 Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human brain
04/17/2003WO2001057214A3 Human transporter proteins and polynucleotides encoding the same
04/17/2003WO2000002548A3 Inhibitors of proteasomal activity for stimulating bone and hair growth
04/17/2003WO1999056766A3 Method for treating ischemia
04/17/2003WO1998004278A3 Tetrapeptide derivatives of dolastatin as antitumor agents
04/17/2003WO1994020127A9 Hla-a2.1 binding peptides and their uses
04/17/2003US20030074695 Plant diacylglycerol O-acyltransferase and uses thereof
04/17/2003US20030074691 Resistance to viruses and viroids in transgenic plants and animals expressing dsRNA-binding protein
04/17/2003US20030074680 Generation of animal food products having amplified ribs; obtain embryos, transform with vector, implant embryo into mammal, test progeny for expression of transgene, process progeny for food
04/17/2003US20030074679 Administration of nucleic acid sequence to female animal to enhance growth in offspring
04/17/2003US20030074142 Coincidence detection programmed media and system
04/17/2003US20030073852 Anticancer agents
04/17/2003US20030073829 Nucleotide sequences coding polypeptides for use in the treatment of eating disorders
04/17/2003US20030073827 Flea head, nerve cord, hindgut and malpighian tubule nucleic acid molecules, proteins and uses thereof
04/17/2003US20030073823 Polypeptide for use in the treatment of cancer, cardiovasular disease, and immunological disorders
04/17/2003US20030073822 Blood group antigen fusion polypeptides and method of use thereof
04/17/2003US20030073821 Antibody for use in human therapeutics and diagnostics
04/17/2003US20030073819 PGC-1, a novel brown fat PPARgamma coactivator
04/17/2003US20030073810 Nucleotide sequence codin polypeptide for use in the diagnosis and treatment of nervous system and cancer disorders
04/17/2003US20030073809 Nucleotide sequence codin polypeptide for use in the diagnosis and treatment of nervous system and cancer disorders
04/17/2003US20030073677 Synergistic mixtures; anticancer agents; 2-(2 -methyl-4-thiazolyl)ethenyl)-4,17-dioxabicyclo(14.1.0)heptadecane-5,9 -dione or 4-aza-17-oxabicyclo(14.1.0) heptadecane-5,9-dione or 1-aza-13-cyclohexadecene-2,6-dione or 1-oxa-13-cyclohexadecene-2,6-dione derivatives
04/17/2003US20030073662 Regulation of cellular functions by ectopic expression of non-endogenous cell signalling receptors
04/17/2003US20030073661 Method of modulating or examining Ku70 levels in cells
04/17/2003US20030073657 Use of alpha 1-antichymotrypsin polypeptides, or nucleic acids encoding them, or of a cell which is expressing an ACT polypeptide, or a nucleic acid encoding it, for treatment and/or prevention of diabetes-associated and/or arterial poorly healing wounds and for identifying pharmacologically active substances
04/17/2003US20030073656 Using a tyrosine kinase receptor inhibitor
04/17/2003US20030073653 Method for transferring nucleic acid into striated muscles
04/17/2003US20030073652 Ex-vivo and in vivo factor XII gene therapy for hemophilia A and B
04/17/2003US20030073651 Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
04/17/2003US20030073638 Pharmaceutical composition comprising factor VIIa and anti-TFPI
04/17/2003US20030073637 Method for stimulating connective tissue growth or wound healing
04/17/2003US20030073636 Administering of activated protein c
04/17/2003US20030073634 Methods of treating obesity
04/17/2003US20030073633 Mutants of bone morphogenetic proteins
04/17/2003US20030073632 Controlling gene expression; apoptosis therapy
04/17/2003US20030073631 Improved pharmacological activities, pharmacokinetics and physical properties; modified with 1-acyl-glycerol derivative
04/17/2003US20030073630 Long lasting growth hormone releasing factor derivatives
04/17/2003US20030073629 Omi and domains thereof that disrupt IAP-caspase interaction
1 ... 1864 1865 1866 1867 1868 1869 1870 1871 1872 1873 1874 1875 1876 1877 1878 1879 1880 1881 1882 1883 1884 ... 3163